A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations By Ogkologos - May 12, 2026 212 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BIOMEDE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Study Identifies Potential Drug Target to Prevent Some Liver Cancers February 4, 2022 EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 Triple negative breast cancer drug given initial ‘no’ for NHS in... April 8, 2022 Load more HOT NEWS Answers to Your Questions About the COVID-19 Vaccine PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia
